These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19332770)

  • 1. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
    Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
    Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
    Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
    Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
    Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
    J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.
    Torcuator RG; Thind R; Patel M; Mohan YS; Anderson J; Doyle T; Ryu S; Jain R; Schultz L; Rosenblum M; Mikkelsen T
    J Neurooncol; 2010 May; 97(3):401-7. PubMed ID: 19838627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
    Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
    Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab is active as a single agent against recurrent malignant gliomas.
    Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
    Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
    Bokstein F; Shpigel S; Blumenthal DT
    Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.